Please Wait...

Meet the Bioclinica Financial Lifecycle Solutions Team: Bob Gabriel, Senior Vice President and General Manager, Bioclinica FLS

Bob Gabriel is the Senior Vice President and General Manager of Bioclinica's Financial Lifecycle Solutions (FLS) division. The FLS suite of financial lifecycle products assists with managing the global automation and financial management of clinical trials and includes ClinPay, a proprietary transaction engine and secure online clinical trial payment network; ClinPlan, a budget management and cash forecasting solution; and ClinDebit, a patient reimbursement solution. These solutions are capable of handling budget and forecast development, contract creation and management, contract translation, automated payment generation and accounting and reporting.

Most recently, Bob was Senior Vice President, Professional Services with Information Builders, providers of business intelligence and process integration solutions to the pharmaceutical R&D, healthcare, banking and financial and insurance sectors, where he had global responsibility for consulting, operations and delivery functions. His 30-year career also includes senior leadership positions at Siebel, PDS, and Cap Gemini, giving him in-depth knowledge of complex ecosystems comprising enterprise resource planning (ERP), financial, customer relationship management (CRM), human resources management system (HRMS) and other critical applications.

While Bob is relatively new to both Bioclinica and clinical trials, his background in delivering professional and consultative services for driving revenue, customer satisfaction, profitability and growth complements the FLS aim of reducing workload, time and costs through automation and unprecedented transparency and workflow.

Bob firmly believes that Bioclinica can become the market leader for FLS. Clinverse, before the acquisition by Bioclinica, defined this market starting with their automated payment services. The primary competition continues to be manual financial processes, and although additional companies have entered this space, they tend to offer only a small subset of the full Bioclinica suite. As such, Bob views his new position as a ground-level opportunity to evolve the value proposition of FLS and further establish the market, by facilitating quicker and more accurate payments leading to increased site and subject satisfaction—his goal is to establish Bioclinica as the number one payment system in the market.

Six Reasons Infographic

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

[Fun Friday] Now that's using you noodle! Ck this out in @RandDMagazine https://t.co/o5h9O1ScBF
bioclinica (7 hours ago)
FDA, NIH & Industry Advance Templates for Clinical Trial Protocols | RAPS https://t.co/Cqda7fLQZf
bioclinica (Yesterday)
Significant Safety Events Found in a Third of FDA-Approved Drugs, Study Finds | RAPS https://t.co/mAHe42W4or
bioclinica (Yesterday)
FDA Official Highlights Foreign Supply Chain Challenges | RAPS https://t.co/qHDtoRw9MS
bioclinica (Yesterday)
RT @MySCRS: Survey finds 50% of Americans are unaware of #ClinicalTrials, reported by @EdClinical. https://t.co/57x8gtXRT0
bioclinica (Yesterday)
RT @ACROhealth: Recent poll data from @ResearchAmerica, 59% of those polled said their family’s health has been improved by clinical resear…
bioclinica (Yesterday)

Latest Blogs: